Volume 20, Number 7—July 2014
Research
Changes in Capsule and Drug Resistance of Pneumococci after Introduction of PCV7, Japan, 2010–2013
Table 2
Year-to-year changes in prevalence of vaccine and nonvaccine serotypes of Streptococcus pneumoniae in children after introduction of PCV7, Japan, April 2010–March 2013*
Disease and serotype | Isolates, no. (%) |
p value | ||
---|---|---|---|---|
2010, n = 300† | 2011, n = 146‡ | 2012, n = 156§ | ||
Meningitis | 0.006 | |||
VT | 42 (14.0) | 17 (11.6) | 6 (3.8) | |
NVT |
20 (6.7) |
17 (11.6) |
15 (9.6) |
|
Sepsis and bacteremia | <0.001 | |||
VT | 111 (37.0) | 42 (28.8) | 13 (8.3) | |
NVT |
48 (16.0) |
39 (26.7) |
94 (60.3) |
|
Pneumonia | <0.001 | |||
VT | 54 (18.0) | 14 (9.6) | 3 (1.9) | |
NVT |
8 (2.7) |
6 (4.1) |
21 (13.5) |
|
Other | 0.147 | |||
VT | 13 (4.3) | 7 (4.8) | 1 (0.6) | |
NVT |
4 (1.3) |
4 (2.7) |
3 (1.9) |
|
Total | <0.001 | |||
VT | 220 (73.3) | 80 (54.8) | 23 (14.7) | |
NVT | 80 (26.7) | 66 (45.2) | 133 (85.3) |
*PCV7, 7-valent pneumoccal conjugate vaccine; VT, vaccine serotype (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F); NVT, serotypes not included
in PCV7.
†Voluntary vaccination with PCV7.
‡Implementation of Urgent Promotion of Vaccination incentive.
§Just before the introduction of 13-valent PCV.